Cutaneous infection caused by Mycobacterium boenickei due to lipolysis injection: A case report

IF 4.7 3区医学 Q1 INFECTIOUS DISEASES

Journal of Infection and Public Health Pub Date : 2025-06-10 DOI:10.1016/j.jiph.2025.102872

Jiayi Peng , Rui Zeng , Tian Gan, Wenyue Zhang, Ying Shi, Youming Mei, Haiqin Jiang, Jingshu Xiong, Chun Pan, Hongsheng Wang

{"title":"Cutaneous infection caused by Mycobacterium boenickei due to lipolysis injection: A case report","authors":"Jiayi Peng , Rui Zeng , Tian Gan, Wenyue Zhang, Ying Shi, Youming Mei, Haiqin Jiang, Jingshu Xiong, Chun Pan, Hongsheng Wang","doi":"10.1016/j.jiph.2025.102872","DOIUrl":null,"url":null,"abstract":"<div><div>Cosmetic injection has emerged as a significant cause of cutaneous infections associated with rapidly growing mycobacteria (RGM). <em>Mycobacterium boenickei</em>, a rare RGM first isolated from a leg wound in the United States in 2004, has been reported in only six strains worldwide. However, clinical cases of <em>M. boenickei</em> infection have not been displayed in detail. Here we report the first detailed case of <em>M. boenickei</em> infection at an injection site following lipolysis treatment in an immunocompetent woman in China. The pathogen was initially identified through <em>rpoB</em> and <em>hsp65</em> sequencing from DNA extracted from skin lesion, which was further confirmed by whole genome sequencing of the culture. The patient was successfully treated with a combination of rifabutin, moxifloxacin, and clarithromycin based on the result of drug susceptibility test. This case report expands the limited literature on uncommon mycobacteria infections and emphasizes the importance of molecular identification and drug susceptibility test in guiding treatment strategies.</div></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":"18 10","pages":"Article 102872"},"PeriodicalIF":4.7000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Public Health","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876034125002217","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Cosmetic injection has emerged as a significant cause of cutaneous infections associated with rapidly growing mycobacteria (RGM). Mycobacterium boenickei, a rare RGM first isolated from a leg wound in the United States in 2004, has been reported in only six strains worldwide. However, clinical cases of M. boenickei infection have not been displayed in detail. Here we report the first detailed case of M. boenickei infection at an injection site following lipolysis treatment in an immunocompetent woman in China. The pathogen was initially identified through rpoB and hsp65 sequencing from DNA extracted from skin lesion, which was further confirmed by whole genome sequencing of the culture. The patient was successfully treated with a combination of rifabutin, moxifloxacin, and clarithromycin based on the result of drug susceptibility test. This case report expands the limited literature on uncommon mycobacteria infections and emphasizes the importance of molecular identification and drug susceptibility test in guiding treatment strategies.

查看原文本刊更多论文

脂解注射液致伯氏分枝杆菌皮肤感染1例

化妆品注射已成为与快速生长的分枝杆菌（RGM）相关的皮肤感染的重要原因。伯氏分枝杆菌是一种罕见的RGM， 2004年在美国首次从腿部伤口中分离出来，据报道，全世界只有六种菌株。然而，布氏分枝杆菌感染的临床病例尚未详细显示。在这里，我们报告了中国一名免疫功能正常的妇女在脂解治疗后注射部位感染的第一例详细病例。从皮肤病变提取的DNA中通过rpoB和hsp65测序初步鉴定病原菌，并通过培养物的全基因组测序进一步证实。根据药敏试验结果，采用利福布汀、莫西沙星、克拉霉素联合治疗成功。本病例报告扩展了罕见分枝杆菌感染的有限文献，强调了分子鉴定和药敏试验对指导治疗策略的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infection and Public Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -INFECTIOUS DISEASES

CiteScore

13.10

自引率

1.50%

发文量

203

审稿时长

96 days

期刊介绍： The Journal of Infection and Public Health, first official journal of the Saudi Arabian Ministry of National Guard Health Affairs, King Saud Bin Abdulaziz University for Health Sciences and the Saudi Association for Public Health, aims to be the foremost scientific, peer-reviewed journal encompassing infection prevention and control, microbiology, infectious diseases, public health and the application of healthcare epidemiology to the evaluation of health outcomes. The point of view of the journal is that infection and public health are closely intertwined and that advances in one area will have positive consequences on the other. The journal will be useful to all health professionals who are partners in the management of patients with communicable diseases, keeping them up to date. The journal is proud to have an international and diverse editorial board that will assist and facilitate the publication of articles that reflect a global view on infection control and public health, as well as emphasizing our focus on supporting the needs of public health practitioners. It is our aim to improve healthcare by reducing risk of infection and related adverse outcomes by critical review, selection, and dissemination of new and relevant information in the field of infection control, public health and infectious diseases in all healthcare settings and the community.